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ABSTRACT
Despite advancements in cancer therapeutics, acute myeloid leukemia patients 
over 60 years old have a 5-year survival rate of less than 8%. In an attempt to 
improve this, epigenetic modifying agents have been combined as therapies in clinical 
studies. In particular combinations with Decitabine and Vorinostat have had varying 
degrees of efficacy. This study therefore aimed to understand the underlying molecular 
mechanisms of these agents to identify potential rational epi-sensitized combinations. 
Combined Decitabine-Vorinostat treatment synergistically decreased cell 
proliferation, induced apoptosis, enhanced acetylation of histones and further 
decreased DNMT1 protein with HL-60 cells showing a greater sensitivity to the 
combined treatment than OCI-AML3. Combination therapy led to reprogramming of 
unique target genes including AXL, a receptor tyrosine kinase associated with cell 
survival and a poor prognosis in AML, which was significantly upregulated following 
treatment. Therefore targeting AXL following epi-sensitization with Decitabine and 
Vorinostat may be a suitable triple combination. To test this, cells were treated with 
a novel triple combination therapy including BGB324, an AXL specific inhibitor. Triple 
combination increased the sensitivity of OCI-AML3 cells to Decitabine and Vorinostat 
as shown through viability assays and significantly extended the survival of mice 
transplanted with pretreated OCI-AML3 cells, while bioluminescence imaging showed 
the decrease in disease burden following triple combination treatment. 
Further investigation is required to optimize this triple combination, however, 
these results suggest that AXL is a potential marker of response to Decitabine-
Vorinostat combination treatment and offers a new avenue of epigenetic combination 
therapies for acute myeloid leukemia.
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INTRODUCTION
Acute myeloid leukemia (AML) is the most common 
form of adult leukemia with disease heterogeneity 
contributing significantly to variability in patient outcomes. 
Although survival rates of younger patients have increased 
in recent years, there has been little improvement for 
elderly patients (> 60 yrs. old) who still have a 5 year 
survival rate of less than 8% [1]. Although subclassification 
of AML has greatly improved during this time, little 
progression has been made in developing effective targeted 
therapies for the treatment of AML. The current standard 
of care regimen of induction (daunorubicin and cytarabine) 
followed by consolidation is only slightly amended from 
original protocols [2].
Aberrant epigenetic modifications including 
methylation (DNA and histone) and acetylation 
(histone) are key contributors to leukemia initiation and 
maintenance [3]. A number of epigenetic modifying 
therapies (EMTs) have shown promise in reversing these 
abnormal patterns and reinstating an epigenetic landscape 
that resembles a more normal state. As early as 1999, 
DNA methyltransferase inhibitors (DNMTi) and histone 
deacetylase inhibitors (HDACi) were shown to have 
synergistic antitumor activities through the re-expression 
of silenced genes [4]. 
DNMTi 5-aza-2′-deoxycytidine (Decitabine) and 
HDACi Vorinostat (SAHA), have been examined as single 
agent therapies for the treatment of AML [5, 6]. In an 
attempt to improve efficacy, various combination therapies 
have been tested, many of which have been extended to 
clinical trial [7, 8]. Significant variability in the degree 
of efficacy has been reported for Decitabine treatment in 
combination with Vorinostat from a response rate of 14% 
for sequential treatment to 46% for concurrent treatment 
in AML and myelodysplastic syndrome [9]. 
The ability of these EMTs to reverse aberrant 
epigenetic marks and re-sensitize or ‘epi-sensitize’ some 
tumors to treatments to which they had acquired resistance, 
[10–12] makes them an attractive therapeutic avenue for 
further development. Although this re-sensitizing effect is 
seen in some instances, this is not always the case as a 
number of studies have reported [13, 14]. None-the-less, 
their perceived reduced toxicities make it an attractive 
option for patients unfit for the current more toxic regimens 
[15, 16]. While Decitabine and Vorinostat have shown 
synergistic in vitro anti-tumor effects in both hematological 
malignancies and various solid tumors, [17–21] 
the molecular mechanisms are not fully understood 
and require further consideration. This study aimed to 
investigate the synergistic affects of Decitabine-Vorinostat 
(DV) combination treatment in AML subtypes, identify 
candidate mechanisms associated with disease subtype-
specific sensitivity and identify pathways that could be 
targeted following epi-sensitization with DV treatment. 
Combination gene expression signatures were obtained 
from AML subtypes and the receptor tyrosine kinase AXL 
was identified as a sensitivity-associated candidate and 
potential target for triple combination therapy. 
RESULTS
The sequential addition of Vorinostat to 
Decitabine primed cells results in a synergistic 
reduction in cell viability 
Single agent treatment with Decitabine or 
Vorinostat resulted in reduced viability of AML cell 
lines. IC50 concentrations for OCI-AML3 and HL-60 
cells were in the low micro-molar range for each agent 
(Supplementary Figure 1). To evaluate potential synergy 
between these EMTs, cell lines were treated with a range 
of dose combinations (concurrent and sequential) and the 
combination index (CI) was calculated using Calcusyn 
software as described in the methods. The doses chosen 
for combination studies (DAC 0.1-0.4 µM and VOR 0.25-
1 µM) were shown previously in our lab to avoid large-
scale cytotoxic cell kill. Sequential dose combinations 
reduced cell viability (Figure 1A) further than single agent 
treatments, achieving a high degree of synergy at lower 
concentrations of each agent while the concurrent regimen 
required higher doses to achieve only a minor synergistic 
effect as determined by the CI value (Supplementary 
Figure 2). The degree of synergy was more notable in 
HL-60 compared to OCI-AML3 cells. Due to a greater 
degree of synergy found using sequential dosing compared 
to concurrent dosing, this schedule was taken forward for 
further analysis. The combination index for the four dose 
combinations taken forward are highlighted in Figure 1B. 
Those taken forward provided a combination with a low 
degree and high degree of synergy for comparison. All 
combination index values for sequential doses tested are 
outline in Supplementary Table 1.
Decitabine/Vorinostat combination treatment 
induced apoptotic cell death 
Cell cycle profiling highlighted the difference in 
cell sensitivity between the OCI-AML3 and HL-60 cell 
lines. The most notable effects were an increase (~10%) in 
the G1 phase following single agent Vorinostat treatment 
in the OCI-AML3 cells and an increase in the SubG1 
population from 1% to 7% and 11% to 30% in the OCI-
AML3 and HL-60 cells respectively following higher dose 
DV combination treatment (Figure 2A). 
Annexin V and PI staining confirmed a significant 
increase in apoptotic cell death following DV combination 
treatment compared to the control and single treatments. 
Higher dose DV treatment significantly reduced the live 
cell population, increased the early apoptotic population 
(FITC+/PI-) by 23% in the OCI-AML3 cells, decreased 
it by 5% in the HL-60 cells and further increased the late 
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apoptotic population (FITC+/PI+) by 7% and 16% in OCI-
AML3 and HL-60 cells respectively relative to the control 
(Figure 2B–2C). This highlights a greater sensitivity in the 
HL-60 cells to DV combination treatment.
The addition of Vorinostat to decitabine primed 
cells enhanced caspases activity
To determine whether the increase in apoptosis 
was due to the activation of caspase enzymes, the level 
of caspase cleavage following single agent treatment and 
combination treatment were assessed. While the higher 
dose of Vorinostat alone had a minimal effect on caspase 
3/7 activity in both cell lines (~1 fold), Decitabine alone 
enhanced caspase 9 (1 fold) and caspase 3/7 (2 fold) 
activity in OCI-AML3 cells, while increasing caspase 8 
(1 fold), caspase 9 (4 fold) and caspase 3/7 (4 fold) activity 
in HL-60 cells (Figure 3A). High dose DV combination 
treatment synergistically increased the levels of caspase 
8, 9 and 3/7 activity further; 7, 2 and 4 fold respectively 
Figure 1: Sequential Decitabine and Vorinostat combination treatment synergistically inhibits AML cell viability. 
(A) OCI-AML3 (Top) and HL-60 (Bottom) cells were treated with DAC (0.1 µM, 0.2 µM and 0.4 µM), VOR (0.25 µM, 0.5 µM, 0.75 µM 
and 1 µM) and all DV combination doses in a sequential manner for a total of 72 hours. Cell viability was measured using a CellTitre-
Glo® assay. (B) Viability percentage was used to calculate the combination index by Calcusyn software. The combination index for each 
combination is depicted in the graph. The Fraction affected (FA) by treatments and combination index (CI) values for candidate doses taken 
forward are highlighted in this figure. Data represent mean ± SEM; n = 3 (***= p < 0.001; **= p < 0.01; *= p < 0.05).
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Figure 2: Combined Decitabine and Vorinostat treatment induces an increase in apoptosis in AML cell lines. OCI-AML3 
and HL-60 cells were treated with 0.1 µM DAC, 0.25 µM and 0.75 µM VOR and both DV combination doses in a sequential manner. 
Cells were harvested and the cell cycle profile of (A) OCI-AML3 (left) and HL-60 (right) cells following treatment was analysed by FACS 
analysis. Annexin V PI staining and the percentage induction of early and late apoptotic cell populations were quantified by FACS analysis 
in OCI-AML3 and HL-60 cells. Results are depicted as dot plots (B) showing the migration from FITC-/PI- (live cells) to FITC+/PI- (early 
apoptotic) and FITC+/PI+ (late apoptotic) populations and quantified as a percentage (C) for each staining condition. Data represent mean± 
SEM; n = 3 (***= p < 0.001; **= p < 0.01; *= p < 0.05).
Oncotarget51433www.impactjournals.com/oncotarget
in OCI-AML3 cells and 4, 10 and 7 fold respectively in 
HL-60 cells (Figure 3A). Immunoblotting analysis further 
confirmed this increase in caspase activity through the 
cleavage of caspase proteins from their inactive to active 
forms (Figure 3B). Supporting the findings from Figure 3A, 
immunoblotting of lysates treated with Decitabine alone 
also showed increased levels of cleaved caspase 3. Caspase 
3, 8 and 9 cleavage is also apparent following the higher 
dose of DV treatment in both cell lines. In addition to 
caspase cleavage, PARP, a downstream target of caspase 
3 was cleaved upon Decitabine treatment in HL-60 cells 
and DV treatment in both cell lines, (Figure 3C) further 
supporting a role for apoptotic signalling following 
combination treatment.
Combination treatment enhanced histone H4 
acetylation and further decrease DNMT1 protein
As expected, Vorinostat treatment alone 
resulted in histone H4 acetylation in a dose dependent 
manner (Supplementary Figure 1B). Western blotting 
demonstrated an enhanced level of histone H4 acetylation 
following combination treatments, particularly at higher 
doses compared to Vorinostat alone (Figure 4A).
We next assessed the impact of combined treatment 
on DNMT1 protein levels and activity. Decitabine alone 
decreased DNMT1 protein levels and LINE-1 CpG 
methylation in a dose dependent manner (Supplementary 
Figure 1B–1C). No further decrease in DNMT1 protein 
levels were observed in OCI-AML3 cells with the addition 
of Vorinostat (Figure 4B); probably as a result of the 
already significantly diminished levels with Decitabine 
alone. Interestingly, the higher dose combination further 
decreased the DNMT1 protein level in HL-60 cells 
(Figure 4B); but did not result in enhanced LINE-1 CpG 
demethylation (Figure 4C). 
Combination treatment generates a unique gene 
expression signature
To identify the subsequent gene expression changes 
induced as a result of altered epigenetic status, microarray 
analysis was performed on OCI-AML3 cells treated with 
single agents or the DV combination while qRT-PCR 
validation of candidate genes identified from this analysis 
was performed on the HL-60 treatments.
Only 11 probe-sets were significantly increased 
following Decitabine treatment alone while 79 probe-sets 
were significantly altered by Vorinostat (72 increased and 
7 decreased) (Supplementary Table 2). In contrast, a total 
of 233 probe-sets had altered expression following DV 
combination treatment (201 increased and 32 decreased) 
(Figure 5A). Figure 5B uses Venn diagrams to show the 
number of probe-sets that were regulated (top panel - up-
regulated or bottom panel - downregulated) by more than 
one treatment condition. This analysis also allowed us to 
identify a sub-category of probe-sets that were unique to 
each treatment group. We identified a total of 140 probe-
sets upregulated and 26 downregulated (118 and 24 genes 
respectively) exclusively following combination treatment. 
Partek gene ontology (GO) and the DAVID database 
[22, 23] analysis of the expression data identified immune 
response, regulation of cell death, regulation of cell 
proliferation and response to oxidative stress as highly 
enriched processes (Figure 5C). A subset of 27 genes 
were chosen at random from those listed in the enriched 
pathways highlighted in Figure 5C for validation by qRT-
PCR. Analysis of this data showed that the expression levels 
detected by qRT-PCR (19 upregulated and 8 downregulated) 
correlated strongly with the microarray results (r2 = 0.5972; 
Figure 5D).  The receptor tyrosine kinase AXL was 
identified as one of the most upregulated genes from both 
the microarray and validation studies and is highlighted by 
the arrow on the heat map in Figure 5A and on the linear 
regression analysis presented in Figure 5D. Interestingly, 
this gene is also involved in each of the most highly enriched 
processes listed in Figure 5C. On further investigation of 
the microarray data, a number of AXL associated/target 
genes were identified as being upregulated following DV 
treatment (Supplementary Figure 3A–3C). These included 
TWIST and SOCS1 but not SOCS3 all of which aim to 
suppress pro-inflammatory signals. In addition, an increase 
in phospho-ERK1/2, a known downstream AXL signaling 
molecule was observed following DV treatment in OCI-
AML3 cells (Supplementary Figure 3D). 
Combination treatment induces upregulation of 
AXL protein levels in OCI-AML3 cells but not in 
HL-60 cells
AXL is known to contribute to cell proliferation, cell 
survival and drug resistance and was selected for further 
study. Validation by qRT-PCR confirmed an increase in 
AXL expression (~18 fold) following combination but 
not by either single agent treatment in OCI-AML3 cells 
(Figure 6A). Vorinostat treatment of Decitabine primed 
cells resulted in a continuous increase in expression of AXL 
over the 24-hour time course confirming a combination 
dependent effect (Figure 6B). This combined treatment 
increase in AXL gene expression was also observed in 
HL-60 cells (Figure 6C).  However, unlike OCI-AML3 
cells, the increased gene expression in HL-60 cells did not 
translate into an increase at the protein level.  In fact, AXL 
protein was undetectable in the HL-60 cell line following 
all treatments (Figure 6D).  The mechanism of AXL 
turnover in HL-60 cells warrants further investigation. 
Not only is AXL upregulated in AML cells lines, 
but the use of an online gene expression tool Bloodspot 
[24] (Supplementary Figure 4A) has demonstrated that 
this expression pattern is translated in the clinical setting, 
where AXL is upregulated in a number of AML subgroups 
compared to normal hematopoietic counterparts. 
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Figure 3: Combined Decitabine and Vorinostat treatment induces caspase activation and Parp cleavage in AML cell 
lines. OCI-AML3 and HL-60 cells were treated with 0.1 µM DAC, 0.25 µM and 0.75 µM VOR and both DV combination doses in a 
sequential manner. (A) Caspase activities were analysed in OCI-AML3 (top panel) and HL-60 (bottom panel) cells using Caspase 3/7 (left), 
8 (centre) and 9 (right) Glo assays. Relative light units were normalised to the percentage of viable cells. (B) Caspase cleavage and (C) Parp 
cleavage of OCI-AML3 (left panel) and HL-60 (right panel) cells following each treatment were assessed by western blot analysis of total 
cell lysate. Actin is used as a loading control. Data represent mean± SEM; n = 3 (***= p < 0.001; **= p < 0.01; *= p < 0.05).
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H3K9ac contributes to the upregulation of AXL 
in OCI-AML3 cells
Decitabine has previously been reported to alleviate 
AXL promoter methylation and induce re-expression in 
cell lines [25]. Specific CpG sites, acH3K9 and H3K9me3 
marks within the AXL gene were further examined to 
investigate potential mechanisms of regulation following 
DV treatment in OCI-AML3 cells. As expected, 
Decitabine alone reduced promoter methylation levels, 
Vorinostat alone had no significant effect on methylation 
and the DV combination showed methylation levels 
Figure 4: Combined Decitabine and Vorinostat treatment enhances histone acetylation and further decreased DNMT1 
expression in AML cell lines. OCI-AML3 and HL-60 cells were treated with 0.1 µM DAC, 0.25 µM and 0.75 µM VOR and both 
DV combination doses in a sequential manner. Western blot analysis of total cell lysates was used to assess the levels of (A) histone H4 
acetylation and (B) DNMT1 protein in OCI-AML3 (left) and HL-60 (right) cells following treatment. Actin is used as a loading control. 
Matching samples were taken for methylation analysis. (C) DNA was extracted, bisulfite converted and CpG methylation of the human 
LINE-1 sequence was quantified by pyrosequencing to estimate levels of global DNA methylation following each treatment in OCI-AML3 
and HL-60 cells. Data represent mean± SEM; n = 3 (***= p < 0.001; **= p < 0.01; *= p < 0.05).
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similar to Decitabine alone (Figure 7A). This indicates 
that Vorinostat does not contribute further to the promoter 
demethylation effects of Decitabine. To further investigate 
the histone acetylation observed following Vorinostat 
treatment (Figure 4A and Supplementary Figure 1B) we 
identified increased acH3K9 activation and decreased 
H3K9me3 repressive mark status of AXL in a myeloid 
cell background (K562) within the publically available 
ENCODE [26–28] database (Figure 7B).  A series of ChIP-
qPCR experiments showed an enrichment of acH3K9 in 
both the promoter and gene body of AXL following DV 
combination in OCI-AML3 cells compared to untreated 
controls. H3K9me3 levels remained low even following 
DV treatment while levels of H3K9me were moderately 
enriched following DV combination (Figure 7C).
BGB324 enhanced the anti-leukemic effect of the 
Decitabine-Vorinostat combination
To determine if adding the AXL specific inhibitor 
BGB324 to the DV combination enhanced the therapeutic 
effect, and as AXL expression was found to increase at 
Figure 5: Combined Decitabine and Vorinostat treatment induces unique gene expression changes in AML cell lines. 
OCI-AML3 cells were treated with 0.1 µM DAC, 0.75 µM VOR and the DV combination in a sequential manner. RNA was extracted, 
processed to cRNA and hybridised to Affymetrix U133 Plus 2 array chips (n = 3). Following processing of array chips, CEL files were 
uploaded to Partek Genomic Suite and an ANOVA analysis performed to detect differentially expressed probe-sets between the control 
and each treatment group. (A) Hierarchical clustering performed on 233 probe-sets identified as differentially expressed between the 
control and the DV combination treatment (upregulated probe-sets = red; downregulated probe-sets = green). Black arrow indicates AXL 
gene expression (B) Differential probe-set lists were overlapped to identify probe-sets (genes) that were altered uniquely following DV 
combination treatment. (C) Probe-sets found to be uniquely altered following DV treatment were subjected to Partek gene ontology 
analysis identifying processes specifically enriched with this treatment. (D) A cohort of 27 genes (19 upregulated and 8 downregulated) 
uniquely altered following DV combination treatment were chosen for qRT-PCR validation. The Pearson correlation coefficient confirms 
correlation between the fold change obtained from the microarray data and qRT-PCR validation (r2 = 0.5972).
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8 hours post Vorinostat addition (Figure 6B); BGB324 was 
added to the DV treated cells at this time point.
Low doses of BGB324 alone (0.25 µM and 0.5 µM) 
had no effect on OCI-AML3 cell viability.  However when 
combined with higher dose DV, 0.25 µM BGB324 and 
0.5 µM BGB324 (DVB triple combination) significantly 
decreased cell viability further than the DV double 
combination (Figure 8A). As HL-60 cells do not express 
AXL, BGB324 appears to have a non-specific induced 
toxicity in HL-60 cells. At the doses used, a reduction 
in cell viability (~15–20%) was observed. Following 
DVB treatment there appears to be an additive effect of 
BGB324 addition rather than a synergistic effect as the 
viability is reduced by ~20% more than DV treatment 
alone (Supplementary Figure 5). 
To further examine the effects of BGB324 on 
leukemic cell growth and disease development, luciferase-
expressing OCI-AML3 cells were treated in vitro with 
the DVB triple combination and transplanted into 
NSG recipient mice. Single agent treatment alone had 
no significant effect on survival of the transplanted 
mice compared to control (median survival: 33 days) 
(Supplementary Figure 6). Throughout the time course 
the double combination treatment arm showed reduced 
leukemic burden, which was further reduced in the triple 
DVB combination arm (Figure 8B). Figure 8B also shows 
Figure 6: Combined Decitabine and Vorinostat treatment induces AXL expression in AML cell lines. OCI-AML3 and HL-
60 cells were treated with 0.1 µM DAC, 0.75 µM VOR and the DV combination in a sequential manner. (A) qRT-PCR analysis confirmed an 
increase in AXL gene expression in OCI-AML3 cells following DV combined treatment. (B) AXL expression increased in a time dependent 
manner (24-hour time course) following the addition of Vorinostat to Decitabine primed OCI-AML3 cells. (C) qRT-PCR analysis also 
confirmed an increase in AXL gene expression in the HL-60 cells following DV combined treatment. (D) Western blot analysis of total cell 
lysate confirms an increase in AXL protein levels following DV combination treatment in OCI-AML3 cells. No detectable levels of AXL 
were found in the HL-60 cells prior to or following treatment. Human colon cancer cell line, HCT-116 cells were used as a positive control 
for high AXL expression. Actin is used as a loading control. Data represent mean ± SEM; n = 3 (***= p < 0.001, **= p < 0.01).
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a histogram depicting the average luminescence intensity 
obtained from the control, DV and DVB cohorts following 
identification of each region of interest-ROI (example of 
ROI shown in Supplementary Figure 6A). The DV cohort 
showed reduced luminescence intensity compared to 
the control; this was further significantly reduced in the 
DVB cohort. Due to the aggressive nature of the OCI-
AML3 cells, leukemia burden was not a determinant of 
mouse survival.  However, mice transplanted with DV 
treated cells tended to survive longer (n~4 days) than mice 
receiving vehicle or single agent treatments (Supplementary 
Figure 6B). A significant extension in survival of mice 
treated with the triple DVB combination compared to the 
control group (n~13 days, p value = 0.0049) and DV group 
(n~9 day, p value = 0.0316) was observed (Figure 8C). 
Together, these data support the use of epi-sensitization 
and multi-step regimens to identify clinically relevant 
combination therapies to optimize AML patient treatment.
DISCUSSION
A major advantage of combined epigenetic therapy 
is the ability to lower the effective drug concentration, 
with associated reduction in toxicity, whilst increasing the 
therapeutic efficacy of cancer therapy. This may reduce 
adverse side effects rendering many current cytotoxic agents 
more tolerable, in particular for elderly patients, while at the 
same time improving patient outcome or survival. 
A number of studies [7, 9, 29] have assessed the 
safety, tolerability and anti-leukemic effect of Decitabine 
and Vorinostat in AML. Reports from clinical trials in 
AML and other leukemias suggest that patients respond 
better when treated with a concurrent dosing schedule 
[9, 29]. In contrast, a phase I clinical study in solid tumors 
and Non-Hodgkin lymphoma reports that a sequential 
schedule was more effective [30]. Experiments have also 
showed greater gene reactivation following sequential 
Figure 7: Combined Decitabine and Vorinostat regulate AXL expression through altered DNA and histone epigenetic 
modifications. OCI-AML3 cells were treated with 0.1  µM DAC, 0.75 µM VOR and the DV combination in a sequential manner. 
(A) AXL promoter methylation of bisulfite treated DNA from each treatment group was assessed by pyrosequencing using primers specific to 
the AXL promoter region. (B) Publically available ENCODE data was used to identify the enrichment of epigenetic marks (ac, me and me3) 
on H3K9 at the AXL promoter and gene body. (C) ChIP-qPCR analysis of acH3K9, H3K9me and H3K9me3 localisation at the AXL promoter 
and gene body in OCI-AML3 cells following treatment. Data represent mean± SEM; n = 3 (***= p < 0.001; **= p < 0.01; *= p < 0.05).
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treatment with Decitabine followed by the HDAC 
inhibitor [18, 31]. The principal objective of this study 
was to assess the combined effects of Decitabine and 
Vorinostat in AML cells, to investigate the gene expression 
signature associated with combined treatment and to 
identify possible epi-sensitized combinations. 
Cognizant of the differences in response between 
clinical scheduling and the in vitro studies, we took 
forward two different regimens; a) Decitabine and 
Vorinostat administered at day 0 for a total of 72 hours 
and b) Decitabine administered at day 0 for 48 hours with 
the addition of Vorinostat at day 2 for 24 hours. Due to the 
Figure 8: Decitabine/Vorinostat/BGB324 triple combination treatment prolonged the survival and decreased the 
leukemic burden in mice. OCI-AML3 luciferase expressing cells were treated with 0.1 µM DAC, 0.75 µM VOR, 0.5 µM BGB324 and 
the double DV and triple DVB combination in a sequential manner.  (A) The viability of OCI-AML3 luciferase cells was assessed using 
the CellTitre-Glo® assay and represented as percentage of control. Data represent mean ± SEM; n = 3 (***= p < 0.001; **= p < 0.01; 
*= p < 0.05). (B) 1.5 × 106 OCI-AML3 luciferase cells (treated in vitro with vehicle control, double DV and triple DVB combinations in 
a sequential manner for 72 hours) were transplanted via tail vein injection into NSG mice (n = 5 per treatment group). Bioluminescence 
imaging commenced 15 days post transplantation. Representative images taken at day 29 post transplantation of surviving mice show 
the disease burden in mice that received control (top), double DV (middle) and triple DVB (bottom) treated cells. Average luminescence 
intensity for each cohort is shown as Photons/sec/mm/sq (C) Mice were sacrificed at the first sign of illness and Kaplan Meier curves were 
generated comparing the survival of mice that received control treated OCI-AML3 luciferase cells (black line) those that received cells 
treated with the double DV (blue dashed line) and triple DVB (red dashed line) combination (**= p < 0.01; *= p < 0.05).
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requirement for cell division to incorporate Decitabine, we 
decided to prime with Decitabine to allow a maintained 
demethylating effect, followed by Vorinostat treatment to 
induce acetylation. Since HDAC inhibitor activity is much 
more transient, we theorized that if performed in reverse 
(priming with Vorinostat), the increase in acetylation may 
supersede demethylation too far in advance to have any 
significant combinatorial effect. Doses used throughout 
were clinically achievable (as calculated based on Stathis 
et al [30]), and were shown to avoid induction of large 
scale cytotoxic cell kill, induce DNA global demethylation 
and histone acetylation as single agent treatments. 
CI values indicated the degree of synergistic 
inhibition of viability between both agents in HL-60 and 
OCI-AML3 cell lines. Interestingly, cells treated with a 
sequential dosing regimen tended to have a greater degree 
of synergy than concurrent treatments. For this reason, we 
progressed with the sequential regimen to identify potential 
mechanisms for the observed anti-leukemic effect in vitro. 
In addition, we found the HL-60 cells to have a greater 
sensitivity to this treatment compared to the OCI-AML3 
cells, suggesting that different primary AML subtypes may 
exhibit differing degrees of sensitivity to such treatments.
With both single agents having previously been 
shown to induce anti-leukemic effects through mechanisms 
such as cell cycle arrest, induction of apoptosis and re-
expression of silenced genes; we investigated whether 
the synergistic decrease in viability was due to an 
enhancement of one or more of these mechanisms. Low 
doses of Decitabine have little effect on leukemic cell 
cycle however; higher doses induce a G2/M arrest [32]. 
Here we support these findings by showing that low 
micro-molar doses of Decitabine have limited activity on 
the cell cycle of OCI-AML3 cells while the addition of 
Vorinostat enhanced the induction of cell death, shown 
by the increase in Sub G1 population. Although Brodska 
et al. [17] reported similar findings using a concurrent 
combination of Decitabine and Vorinostat; our study shows 
that sequential treatment with lower doses can enhance cell 
kill.  Furthermore we show that the increase in Sub G1 
population following combined treatment is not merely a 
cytotoxic affect but that the treatment signals an increase 
of apoptotic pathways through the cleavage of caspases. 
With increasing evidence supporting the interplay 
between DNA methylation and histone acetylation patterns 
in regulating gene expression, it is rational to hypothesize 
that the combined use of Decitabine and Vorinostat will 
affect the molecular events within the AML cell lines, 
contribute to alter gene expression signatures as reported by 
others [18, 31] and activate survival signals to counteract 
the enhanced anti-leukemic effects. In concordance with 
others [33, 34], we show that sequential combination of 
Decitabine and Vorinostat leads to heightened histone 
acetylation in the OCI-AML3 and HL-60 cell lines. It has 
been known for some time that methyl binding proteins 
such as MeCP2 are known to recruit transcriptional 
repressor complexes which include HDACs, decreasing 
acetylation and inhibiting gene transcription [35–37]. 
A reduction in levels of methylation following DNMTi 
treatment and therefore a reduction in the binding capacity 
of these HDAC containing repressor complexes provides 
a potential explanation for the enhanced levels of histone 
acetylation when these two EMTs are used in combination. 
Further reductions in DNMT1 protein levels were also 
found in HL-60 cells, although less pronounced in OCI-
AML3 cells, possibly due to the already significantly 
diminished DNMT1 levels by Decitabine alone. The 
concept that HDAC inhibitors can decrease DNMT1 
expression is not new. A number of publications describe 
a decrease in DNMT1 at both the mRNA level and protein 
level with Trichostatin A treatment in cancer models 
including; hepatocellular, bladder and breast cancer cell 
lines [38–40]. Zhou et al. suggest a possible mechanism 
whereby DNMT1 is bound to and stabilised by HSP90 and 
that the addition of Trichostatin A mediates the acetylation 
of HSP90, disaggregating the complex and destabilizing 
DNMT1, targeting it for proteasome degradation [40]. 
They also report that Vorinostat acetylates HSP90 in 
breast cancer cells providing a possible similar mechanism 
of action [41]. The reduction of DNMT1 in HL-60 cells 
did not lead to any further reduction in methylation status 
as shown by LINE-1 levels; a longer time frame may be 
needed to assess if the decrease in DNMT1 can lead to 
a reduction in methylation levels and changes in gene 
specific methylation which warrants further study. 
Gene expression signatures induced following 
Decitabine, Vorinostat or the DV combined sequential 
treatments in the OCI-AML3 cell line were determined. 
As expected, low dose Decitabine (0.1 µM) alone had little 
effect on gene expression. Decitabine has a short half-life 
and its effects are reversible, so repeated dosing may be 
required to maintain hypomethylation and increase efficacy 
of this agent. Vorinostat alone had a greater effect on gene 
expression than Decitabine alone. A total of 79 probe-
sets had altered expression levels following Vorinostat in 
comparison to 11 probe-sets being altered with Decitabine 
treatment. Of these 79 probe-sets, 72 (~91%) were induced 
compared to 7 (~9%) repressed. Furthermore the DV 
combination produced a gene expression signature with 
140 probe-sets (≡118 genes) significantly upregulated and 
unique to the combination treatment. This supports the 
concept that removal of methylation from DNA is essential 
for the regulation of many genes but alone is insufficient 
to carry out re-expression and that HDACi’s can reactivate 
genes previously silenced by methylation [18, 31, 42–44] 
Bioinformatics analysis identified that highly enriched 
processes were associated with the immune response, the 
regulation of cell death, regulation of cell proliferation and 
response to oxidative stress. Amongst the re-expressed genes 
were CDKN2A, EIF2AK2, TNFSF10 and XAFI, all of which 
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are associated with cell cycle inhibition or induction of cell 
death through increasing caspase activity and the reduction 
of which are known to be associated with the development 
of leukemia [45–49].The upregulation of a number of 
these genes may provide a link to explain some of the 
enhanced anti-leukemic affects observed throughout this 
study. interferon response were also upregulated following 
combined treatment; these included IFI27, IFIH1, IFIT2, 
ISG20, STAT1, STAT2 and OAS1, some of which are known 
Decitabine target genes, albeit at a higher dose [50] .
AXL was identified as one of the most highly 
expressed genes following DV treatment (18-fold induction) 
and was of particular importance as it is implicated in many 
cancers [51, 52] A number of its oncogenic properties 
include a role in cell proliferation, survival and inhibition 
of apoptosis [53, 54]. The use of Bloodspot data indicate 
that AXL expression is higher in certain subsets of AML 
compared to normal hematopoietic counterparts while 
Ben-Batalla et al. showed that patients expressing higher 
than median AXL levels had a worse prognosis [51].  
A number of therapeutic agents, including 
Decitabine, have been reported to upregulate AXL and 
induce drug resistance [55]. AXL was upregulated with 
the DV combination treatment in OCI-AML3 and HL-60 
cells. Bisulfite pyrosequencing and ChIP-based analysis 
identified that upregulation of AXL was due in part to 
Decitabine-induced reduction in methylation at the 
promoter that was permissive for gene-specific acH3K9 
activation and reduction of H3K9me3 repression. 
The data supports a hypothesis that DV combination 
treatment of AML cells results in epigenetic induction 
of AXL expression which may contribute to the partial 
drug resistance phenotype observed in OCI-AML3 cells, 
relative to the HL-60 cell line where the same dose DV 
combination had a greater level of synergistic decrease 
on cell viability. To test this hypothesis, we challenged 
the DV-treated OCI-AML3 cells with an AXL specific 
inhibitor (BGB324) in novel triple combination pre-clinical 
studies. Triple DVB combination resulted in significantly 
increased disease-free-survival over vehicle, mono or 
dual therapies in transplantation models. More recently, 
BGB324 received orphan drug designation for the use in 
treating AML [51, 56] and in addition, has shown promise 
when combined with immune checkpoint inhibitors. AXL 
and other TAM family members function to dampen the 
innate immune response through inhibition of toll-like 
receptors and their signaling cascades [57]. A recent article 
highlighted a potentially successful therapeutic application 
of the AXL inhibitor in combination with immune 
checkpoint inhibitors anti-CTLA-4/anti-PD1 where they 
stated that these agents induce AXL expression in an 
attempt to evade immune responses [58]. Our study reports 
similar findings whereby high AXL expressing DV treated 
cells increase a number of suppressor of cytokine signalling 
molecules including SOCS1 and TWIST [57, 59]. Further 
studies are required to identify if the increase in SOCS1, 
TWIST and the elevated phospho-ERK1/2 levels following 
DV treatment are in part attributable to AXL signaling 
and whether this may be an attempt by the cells to escape 
eradication through an inflammatory mediated response. 
To address whether the mutational status of each 
cell line could play a role in the sensitivity to BGB324, 
we performed patient survival analysis on a local data set 
which incorporated data from the Microarray Innovations 
in LEukemia (MILE) study [60]. AXL expression was 
correlated with NPM1 and APL status as OCI-AML3 cells 
harbor mutant NMP1 and HL-60 cells were derived form a 
patient with APL t(15;17) . NPM1 status in conjunction with 
AXL levels did not appear to have any significant effect on 
patient survival suggesting that the sensitivity to BGB324 
in the OCI-AML3 cell line is likely attributable to the high 
AXL levels in OCI-AML3 cells and not the mutational 
characteristics of the cell line. Although it did not reach 
significance with the number of patients included in our 
analysis, those with APL and low AXL expression tended to 
have an improved 5-year survival compared to APL patients 
with high AXL expression. This further supports other 
findings that state high AXL expression leads to a worse 
prognosis in leukemia patients (Supplementary Figure 4B). 
However, the enhanced sensitivity to DV treatment in the 
HL-60 cell is more likely explained by the absence of 
AXL protein/signaling in this cell line. Unlike the cell line, 
patients harboring this translocation my still retain high AXL 
levels and benefit from this novel triple therapy.
Although currently only patients with high AXL 
would appear to be candidates for such treatment, we 
believe that further investigation into combining BGB324 
in a triple epigenetic combination therapy with Decitabine 
and Vorinostat is warranted. Previous studies have shown 
that Decitabine/Vorinostat combination is safe and well 
tolerated in patients both alone and followed by re-
induction chemotherapy, [7, 9] as is the use of BGB324 
as demonstrated through clinical studies in leukemic 
patients [61]. Phase I clinical studies would be required to 
assess the safety and tolerability of this triple combination 
treatment in patients.
In conclusion, this study has characterised the 
synergistic activity of Decitabine with Vorinostat in 
in vitro AML models and identified a potential biomarker 
(AXL) and possible mechanisms of action through gene 
expression profiling. Furthermore, this work has paved the 
way for further development of a novel triple combination 
therapy for the treatment of AML. 
MATERIALS AND METHODS
Materials
Decitabine; 5-aza-2′deoxycitidine (Sigma-Aldrich, 
Dorset, UK) was dissolved in water. Vorinostat; SAHA 
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(SelleckChem, Houston, USA) was dissolved in DMSO. 
BGB324 was a gift from BerGenBio (Bergen, Norway) 
and was dissolved in DMSO; final DMSO for in vitro 
assays was 0.1%.
Cell lines
OCI-AML3 cells (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH, Braunschweig, 
Germany), and HL-60 cells (American Type Culture 
Collection, Middlesex, UK) were maintained in RPMI-
1640 media supplemented with 10% fetal calf serum, 1% 
Pen/Strep and incubated in 5% CO
2
 at 37°C. 
Dosing schedule for combination treatment
Concurrent treatment consisted of Decitabine and 
Vorinostat added at day 0 for 72 hours while sequential 
treatment consisted of Decitabine added at day 0 for 
48 hours and Vorinostat added at 48 hours for a further 
24 hours. Triple combination treatment: cells were treated 
as above for the sequential combination of Decitabine 
and Vorinostat with BGB324 added 8 hours following 
Vorinostat. Single agent controls were treated for the time 
course stated above. Cells were harvested at 72 hours for 
processing and downstream analysis. Only sequential 
Decitabine and Vorinostat combination dosing is referred 
to as DV throughout.
Viability, caspase activity assays and 
combination index calculation
Cell viability and caspase activity was determined 
using the CellTitre-Glo® luminescent viability kit and 
caspase Glo® assays (Promega, Madison, USA) as 
described in the manufacturer’s instructions. Calcusyn 
Software Version 2.1 (Cambridge Computing Imaging Ltd, 
Cambridge, UK) was used to calculate the combination 
index (CI) using the percentage of cells affected. The 
Chou-Talalay method [62] is employed by Calcusyn for 
calculating the CI. The software uses a method based 
on the median effect equation (MEE) derived from the 
mass action law and correlates dose and effect to produce 
the CI value; anything less than one showing a level of 
synergy (closer the number to 0 shows a greater degree of 
synergy) or a number greater than 1 showing antagonism 
between the agents. In this case we used the percentage 
of non-viable cells after treatment (as determined by the 
CellTitre-Glo® assay described above) as the fractional 
affect. This data is input into the software along with the 
dose of all agents used in the combination treatment.
FACS analysis
To assess cell cycle changes, cells were harvested 
and re-suspended in 70% ice-cold ethanol overnight 
followed by staining with propidium iodide mix (40 µg/mL 
PI, 2 ng/ml RNase A). BD FITC Annexin V apoptosis 
detection kit (BD Biosciences, California, USA) was used 
according to the manufacturer’s instructions to assess 
apoptosis. Samples were analysed using LSRII and BD 
FACSDiva software.
Western blot analysis
Cells were washed and lysed using RIPA buffer (50 
mM Tris (pH 7.4), 150 mM NaCl, 5 mM EDTA, 1% triton 
X(X100) and 0.1 % SDS) containing protease inhibitor 
cocktail tablets (Roche Products Ltd, Welwyn Garden 
City, UK) and phosphatase inhibitors (sodium fluoride 
and sodium orthovanadate). Protein concentration was 
quantified according to the manufacturer’s instructions 
(Pierce BCA Protein Assay kit, Thermo Fisher Scientific, 
USA). Total lysates were prepared by adding 10X loading 
buffer to 30 µg of total lysate before denaturation for 
5 minutes at 95oC. Lysates were then electrophoresed on 
various percentage Tris Glycine gels and immunoblotted 
using anti-caspase 8 (Enzo Life Sciences, UK), anti-
caspase 9, anti-caspase 3, anti-acetylated tubulin, anti-
DNMT1, anti-AXL (Cell signalling, Massachusetts, 
USA), anti-hyperacetylated histone H4 (Merck Millipore, 
UK) and anti-PARP (eBioscience, UK) antibodies.
Bisulfite pyrosequencing for global DNA 
methylation analysis
DNA was extracted and bisulfite treated using the 
DNeasy Blood and Tissue Kit and the Epitect Bisulfite Kit 
(Qiagen, Crawley, UK) according to the manufacturer’s 
instructions. Bisulfite DNA underwent PCR using primers 
for the human LINE-1 sequence (Qiagen) and samples 
were sequenced using the Pyromark Q24 Pyrosequencer.
Analysis of gene expression by microarray 
RNA was extracted from biological triplicate 
samples using the RNeasy kit. A maximum of 8 µg of total 
RNA was processed to cRNA and hybridised to Affymetrix 
Human Genome U133 Plus 2.0 Arrays following the 
protocol outlined by Roche Diagnostics (Burgess Hill, 
UK). Arrays were then stained using an Affymetrix 
GeneChip Fluidics Station 450 and scanned using the 
Affymetrix GeneChip Scanner 3000 5G. Analysis of data 
was performed using Partek Genomic Suite Software 
(Partex Incorporated, Missouri, USA). Following CEL file 
importation to Partek Genomic Suite, data were analysed 
using a Robust Multi-array (RMA) analysis to correct for 
background, quantile normalise and summarise the probe 
set intensity into expression measurements. Data was 
subjected to ANOVA analysis and subsequent gene lists 
were created based on the following criteria. 
•	 	Vehicle control  v Decitabine (FDR p < 0.05 and 
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fold change or ≤ –2 or ≥ 2)
•	 	Vehicle control v Vorinostat (FDR p < 0.01 and 
fold change ≤ –4 or ≥ 4)
•	 	Vehicle control v Combination (FDR p < 0.01 
and fold change ≤ –4 or ≥ 4)
Quantitative real time PCR
RNA was extracted using the RNeasy Kit 
(Qiagen) as described by the manufacturer’s protocols 
and reverse transcribed using the High-Capacity cDNA 
reverse transcription kit (Applied Biosystems, Life 
Technologies, UK).
SYBR Green real time quantitative PCR was 
performed using the 7900HT Real-time PCR system 
under optimal cycling conditions. Primers used for mRNA 
quantification were designed in-house using Primer-Blast 
and purchased from Eurofins Genomic (Eurofins Genomic, 
Ebersberg, Germany). Primer sequences used can be found 
in Supplementary Table 3. Validation of microarray studies 
was carried out using RNA matched samples to those used 
for hybridisation to the Affymetrix arrays.
Gene expression is shown as fold change of the 
control treatment and normalised to the endogenous 
controls. The Ct value for each gene was normalised to 
β-Actin and 18S endogenous controls (ΔCt), ΔCt was then 
normalised to the treatment control (ΔΔCt), and the ΔΔCt 
was used to calculate gene expression changes as a fold 
change over control.
ChIP-qPCR
Combination treatments were set up as described in 
the methods section. 1 × 106 cells per IP were harvested 
and fixed in 1% formaldehyde. Cells were washed and 
chromatin was isolated; fixed samples were resuspended 
in LB1 buffer (50 mM Hepes-KOH, pH 7.5, 140 mM 
NaCl, 1 mM EDTA, 10% glycerol, 0.5% IGEPAL, 0.25% 
Triton X-100) for 10 minutes, pelleted and resuspended 
in LB2 buffer (10 mM TrisHCl, pH8, 200 mM NaCl, 
1 mM EDTA, 0.5 mM EGTA) for 5 minutes, pelleted 
and resuspended in LB3 buffer (10 mM TrisHCl, pH8, 
100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% 
NA-deoxycholate, 0.5% N-laurylsarcosine). Cells were 
sonicated for appropriate time to obtain fragments of 
between 200-500 bp. Following sonication, 10% triton 
X-100 was added and chromatin was snap frozen for 
chromatin immunoprecipitation studies. 30 µL beads per 
IP were washed and blocked overnight at 4oC in sterile 
0.5% BSA:PBS. Chromatin was immunoprecipitated 
with chosen antibodies (anti-histone H3 (acetyl K9), 
anti-histone H3 (mono methyl K9) and anti-histone 
H3 (tri methyl K9) (Abcam, UK)) and eluted using 
elution buffer (50 mM Tris pH8, 10 mM EDTA, 1% 
SDS). Chromatin was purified using the QIAquick 
PCR purification kit (Qiagen) as described in the 
manufacturer’s instructions.
Ex-vivo studies
Animal handling was in line with the guidelines set 
out by the UK Animals Scientific Procedures Act 1986. 
The Ethical Review Committee for animal research at 
Queen’s University Belfast approved all experimental 
procedures. The OCI-AML3 luciferase cell line was 
created as follows. OCI-AML3 cells were seeded the 
day before transfection at 5 × 106 cells/10 cm dish and 
grown to approximately 70–80% confluency. Transfection 
of 293T cells was performed using Turbofect (Thermo 
Scientific, Massachusetts, USA) with a molar of 1:3:6 
ratio of VSV-G envelope vector pMD2.G, packaging 
vector psPAX2 (kindly provided by Dr Fabio Liberante) 
and firefly luciferase vector pSLIEW (kindly provided by 
Prof Olaf Heidenreich). Viral supernatant was harvested 
and filtered 72 hours after transfection.  A volume of 
500 µl filtered pSLIEW virus was added to 2 × 105 cells in 
200 µl medium with 8 µg/ml Polybrene (Sigma Aldrich) 
and incubated for 48 hours before selection in neomycin. 
Validation of OCI-AML3 transduction was performed 
using Bruker In Vivo Xtreme imaging system before 
cells were treated and transplanted. Cells were treated 
in vitro with control, each single agent and either 0.1 µM 
Decitabine plus 0.75 µM Vorinostat or 0.1 µM Decitabine 
plus 0.75 µM Vorinostat plus 0.5 µM BGB324. A total 
of 1.5 × 106 cells per mouse were resuspended in PBS 
and transplanted via tail vein injection into recipient NSG 
mice (Charles River, Tranent, UK) - (each treatment group 
n = 5). Mice were imaged for luciferase signal using the 
Bruker In Vivo Xtreme imaging system every second day 
between day 15 and day 37. Mice were sacrificed at the 
first sign of disease and survival extension was assessed.
Statistical analysis
All statistical analysis was performed using 
Graphpad Prism version 5.00 for Windows (California, 
USA). All statistical tests were performed on at least a 
biological replicate of 3.
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